Bay Colony Advisory Group Inc d b a Bay Colony Advisors Has $4.25 Million Holdings in Eli Lilly and Company $LLY

Bay Colony Advisory Group Inc d b a Bay Colony Advisors grew its stake in Eli Lilly and Company (NYSE:LLY) by 7.3% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 5,445 shares of the company’s stock after buying an additional 372 shares during the quarter. Bay Colony Advisory Group Inc d b a Bay Colony Advisors’ holdings in Eli Lilly and Company were worth $4,245,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in the business. O Brien Wealth Partners LLC boosted its holdings in Eli Lilly and Company by 25.5% during the first quarter. O Brien Wealth Partners LLC now owns 59 shares of the company’s stock worth $49,000 after purchasing an additional 12 shares during the last quarter. Ascent Capital Management LLC raised its position in Eli Lilly and Company by 2.5% during the first quarter. Ascent Capital Management LLC now owns 495 shares of the company’s stock worth $409,000 after acquiring an additional 12 shares in the last quarter. Willner & Heller LLC raised its position in Eli Lilly and Company by 1.5% during the first quarter. Willner & Heller LLC now owns 854 shares of the company’s stock worth $705,000 after acquiring an additional 13 shares in the last quarter. Braun Bostich & Associates Inc. raised its position in Eli Lilly and Company by 2.5% during the second quarter. Braun Bostich & Associates Inc. now owns 527 shares of the company’s stock worth $411,000 after acquiring an additional 13 shares in the last quarter. Finally, Rise Advisors LLC raised its position in shares of Eli Lilly and Company by 1.8% in the second quarter. Rise Advisors LLC now owns 732 shares of the company’s stock valued at $571,000 after purchasing an additional 13 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently commented on LLY shares. DZ Bank raised shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research report on Thursday, August 14th. Leerink Partners reiterated a “market perform” rating and issued a $715.00 price objective on shares of Eli Lilly and Company in a report on Thursday, August 7th. Wall Street Zen lowered shares of Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a report on Saturday, September 20th. The Goldman Sachs Group raised their price target on shares of Eli Lilly and Company from $876.00 to $879.00 and gave the stock a “buy” rating in a report on Friday, October 10th. Finally, Morgan Stanley lowered their price target on shares of Eli Lilly and Company from $1,028.00 to $1,023.00 and set an “overweight” rating for the company in a report on Friday, October 3rd. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat.com, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and a consensus price target of $936.47.

Insiders Place Their Bets

In other news, Director Jamere Jackson acquired 200 shares of the business’s stock in a transaction on Friday, August 8th. The shares were purchased at an average cost of $639.56 per share, with a total value of $127,912.00. Following the acquisition, the director directly owned 9,402 shares of the company’s stock, valued at $6,013,143.12. The trade was a 2.17% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Daniel Skovronsky acquired 1,000 shares of the business’s stock in a transaction on Tuesday, August 12th. The shares were purchased at an average cost of $634.40 per share, for a total transaction of $634,400.00. Following the completion of the acquisition, the executive vice president directly owned 137,660 shares in the company, valued at approximately $87,331,504. The trade was a 0.73% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders bought a total of 4,514 shares of company stock worth $2,894,841 in the last three months. 0.13% of the stock is owned by corporate insiders.

Eli Lilly and Company Stock Up 3.5%

Shares of NYSE LLY opened at $842.28 on Friday. The stock has a market capitalization of $797.18 billion, a P/E ratio of 55.05, a P/E/G ratio of 1.21 and a beta of 0.47. The company has a 50-day moving average price of $777.69 and a 200-day moving average price of $770.84. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $935.63. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. The firm had revenue of $17.60 billion during the quarter, compared to analysts’ expectations of $16.09 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The business’s revenue was up 53.9% on a year-over-year basis. During the same period last year, the company earned $1.18 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, equities research analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, December 10th. Investors of record on Friday, November 14th will be given a $1.50 dividend. This represents a $6.00 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date of this dividend is Friday, November 14th. Eli Lilly and Company’s dividend payout ratio is presently 39.22%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.